Internal Medicine, Hematology & Oncology · Fountain Valley, CA
NPI
1376816249
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
18111 Brookhurst St, Ste 6100
Fountain Valley, CA, 92708
Phone (405) 271-4022
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
61,858 services
Medicare patients, 2024
226
Average age 72
Drug cost, 2024
$5.4M
1,199 prescriptions
Company payments, 2025
$5,865
From 58 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anas Raowas was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 1,400 times for 24 patients. In total Anas Raowas billed 61,858 services in 87 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-11-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,400 | 24 | $0.09 | $124 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,224 | 11 | $0.08 | $91.98 |
| 99215 Office E&M - Established | Office | 312 | 123 | $139.42 | $43K |
| 96413 Chemotherapy Administration | Office | 183 | 27 | $106.36 | $19K |
| 96367 Intravenous Infusion, Hydration | Office | 140 | 26 | $23.71 | $3,320 |
| 96415 Chemotherapy Administration | Office | 104 | 13 | $22.81 | $2,373 |
| 99214 Office E&M - Established | Office | 102 | 71 | $96.89 | $9,883 |
| 96127 Behavioral Health Services | Office | 101 | 92 | $3.86 | $390 |
| 96417 Chemotherapy Administration | Office | 89 | 12 | $54.29 | $4,832 |
| 99233 Hospital E&M - Subsequent | Facility | 88 | 48 | $93.05 | $8,188 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 79 | 21 | $0.63 | $50 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 70 | 11 | $5.00 | $350 |
| 96375 Injection Administration | Office | 62 | 13 | $12.71 | $788 |
| 96365 Intravenous Infusion, Hydration | Office | 59 | 32 | $48.00 | $2,832 |
| 96372 Injection Administration | Office | 50 | 14 | $10.95 | $547 |
By year: 2022 $814K for 53,208 services; 2023 $840K for 74,386 services; 2024 $1.3M for 61,858 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anas Raowas prescribed most often to Medicare patients was Anastrozole, with 78 prescriptions and refills. In total Anas Raowas wrote 1,199 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 78 | 216 | 33 | $1,512 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 43 | 43 | 22 | $1,122 |
| Exemestane Generic | 39 | 95 | 20 | $7,143 |
| Revlimid Lenalidomide | 38 | 38 | Under 11 | $660K |
| Diphenhydramine Hcl Generic | 37 | 37 | 14 | $94.97 |
| Letrozole Generic | 37 | 100 | 17 | $778 |
| Acyclovir Generic | 37 | 43 | 14 | $402 |
| Calquence Acalabrutinib Maleate | 29 | 29 | Under 11 | $388K |
| Prochlorperazine Maleate Generic | 28 | 30 | 21 | $729 |
| Verzenio Abemaciclib | 28 | 28 | Under 11 | $413K |
| Xgeva Denosumab | 27 | 29 | Under 11 | $84K |
| Famotidine Famotidine/Pf | 26 | 26 | 11 | $49.69 |
| Hydroxyurea Generic | 25 | 36 | Under 11 | $436 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 25 | 25 | Under 11 | $168 |
| Dexamethasone Sodium Phosphate Generic | 24 | 24 | Under 11 | $124 |
Brand drugs: 462 claims; generic drugs: 737 claims; opioid claims: 63.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anas Raowas $5,865 ($5,865 in general payments such as food, travel and fees) from 58 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $570.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 23 | $570 |
| Janssen Biotech, Inc. JNJ | 20 | $483 |
| Pfizer Inc. PFE | 17 | $384 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 19 | $322 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $308 |
| Celgene Corporation BMY | 13 | $271 |
| Karyopharm Therapeutics Inc. KPTI | 20 | $229 |
| GlaxoSmithKline, LLC. GSK | 17 | $224 |
| Caris MPI, Inc. | 5 | $149 |
| Stemline Therapeutics Inc. | 5 | $148 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.